RICHLAND, WASHINGTON – June 21, 2022 – The growing body of information regarding Isoray, Inc.’s  (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference...